A proof-of-concept study on CGRP plasma levels of migraineurs during a 6-month treatment with ERENUMAB

Abstract The introduction of monoclonal antibodies (mAbs) against calcitonin-gene related peptide (CGRP) or CGRP receptors in the treatment of migraine raised concerns on the possible risks associated to the long-term inhibition of CGRP physiological functions. In this proof-of-concept study, we hav...

Full description

Bibliographic Details
Published in:The Journal of Headache and Pain
Main Authors: Giuseppe Tringali, Catello Vollono, Paolo Calabresi, Pierluigi Navarra
Format: Article
Language:English
Published: BMC 2020-10-01
Subjects:
CGRP
CGRP receptor
Monoclonal antibodies
Erenumab
Migraine
Online Access:http://link.springer.com/article/10.1186/s10194-020-01193-4

Internet

http://link.springer.com/article/10.1186/s10194-020-01193-4

Similar Items